Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Small Cell Lung Cancer Pipeline Report
- DelveInsight’s Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
- The leading companies working in the Small Cell Lung Cancer Market include Ascentage Pharma, Merck & Co., AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, and others.
- Promising Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Berzosertib, Topotecan, Atezolizumab, Lurbinectedin, Carboplatin, Etoposide, and others.
- November 2023: Hoffmann- La Roche announced a study of Phase 1 clinical trials for RO7616789 and Tocilizumab. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants with advanced stage small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) will be enrolled in the study.
- November 2023: Suzhou Zelgen Biopharmaceuticals Co.,Ltd announced a study of Phase 1 & 2 clinical trials for ZG006. This is a multi-center, open-label, Phase Ⅰ/Ⅱ clinical study of ZG006 for the treatment of participants with small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment.
- November 2023 BeiGene announced a study of Phase 2 clinical trials for Ociperlimab, Tislelizumab and Concurrent Chemoradiotherapy. This phase 2 trial examining the combination of ociperlimab plus tislelizumab plus cCRT is expected to provide valuable data to advance treatment options in the serious unmet medical need population of LS-SCLC patients. Immunotherapy combined with chemoradiotherapy may have a synergetic anti -cancer activities. The combination of anti-TIGIT antibody and anti-PD-1/L1 antibody may augment the immune effect with tolerable safety profile. The novel therapeutic strategy with dule immune therapy in combination with CRT is expected to provide valuable data to advance treatment options in the population of LS-SCLC patients.
- November 2023: G1 Therapeutics Inc. announced a study of Phase 4 clinical trials for Trilaciclib and Topotecan. This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival. The study will include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. Patients randomized in this study will receive trilaciclib/placebo + topotecan 1.5 mg/m2 until disease progression, unacceptable toxicity, withdrawal of consent, Investigator decision to discontinue treatment, or the end of the trial, whichever comes first.
- November 2023: Bristol-Myers Squibb announced a study of Phase 2 clinical trials for Carboplatin, BMS-986012, and Etoposide. The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).
Request a sample and discover the recent advances in Small Cell Lung Cancer Treatment Drugs @ Small Cell Lung Cancer Pipeline Report
In the Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Small Cell Lung Cancer Overview
Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non–small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics. Small cell lung carcinoma (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa.
Find out more about Small Cell Lung Cancer Therapeutics Assessment @ Small Cell Lung Cancer Preclinical and Discovery Stage Products
Small Cell Lung Cancer Emerging Drugs Profile
- AMG 757: Amgen
- APG-1252: Ascentage Pharma
Small Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Small Cell Lung Cancer. The Small Cell Lung Cancer companies which have their Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Phase III include, Ipsen.
DelveInsight’s Small Cell Lung Cancer pipeline report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Small Cell Lung Cancer Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Learn more about the emerging Small Cell Lung Cancer Pipeline Therapies @ Small Cell Lung Cancer Clinical Trials Assessment
Scope of the Small Cell Lung Cancer Pipeline Report
- Coverage- Global
- Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Small Cell Lung Cancer Companies- Ascentage Pharma, Merck & Co., AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, and others.
- Small Cell Lung Cancer Pipeline Therapies- Berzosertib, Topotecan, Atezolizumab, Lurbinectedin, Carboplatin, Etoposide, and others.
Dive deep into rich insights for new drugs for Small Cell Lung Cancer Treatment, Visit @ Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Small Cell Lung Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Small Cell Lung Cancer Collaboration Deals
- Late Stage Products (Phase III)
- Pembrolizumab: Merck & Co
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Dostarlimab: GlaxoSmithKline
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AMG 757: Amgen
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- S 055746: Vernalis
- Drug profiles in the detailed report…..
- Inactive Products
- Small Cell Lung Cancer Key Companies
- Small Cell Lung Cancer Key Products
- Small Cell Lung Cancer- Unmet Needs
- Small Cell Lung Cancer- Market Drivers and Barriers
- Small Cell Lung Cancer- Future Perspectives and Conclusion
- Small Cell Lung Cancer Analyst Views
- Small Cell Lung Cancer Key Companies
- Appendix
For further information on the Small Cell Lung Cancer Pipeline therapeutics, reach out to Small Cell Lung Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
){kind=link}